Pharma Focus Asia

Samsung Biologics Invests US $1.46 billion (KRW 1.9 trillion) for the Construction of Fifth New Plant

Introduction:
Samsung Biologics plans for the contruction of fifth new plant. The new site will be located at Songdo, South Korea.

Features:
The new facility is the second Bio campus covering an area of 96,000m2 and holding a capacity of 180,000 litres.

The plant is expected to further maximise its operational efficiency, allowing to leverage existing talent, knowledge and technology gained through the plant's 1 to experience, while implementing advanced digitisation and sustainability capabilities.

This new facility will help customers with even greater innovation and services that will increase speed to the current market and flexibility.

The current Plants 1, 2, and 3 are under near-full utilisation and Plant 4 started partial operations in October last year, and is expected to be fully operational by the middle of the year.

The contruction of the new facility begins in first half of 2023 and expected to be start its operations in 2025.

Specifications:

NameSamsung Biologics
TypeNew Construction
Budget$1.46 billion (KRW 1.9 trillion)
Year2025
magazine-slider-image
magazine-slider-image
Cytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024